SHH:600380
Joincare Pharmaceutical Group Industry Co.,Ltd. · SHH · Healthcare · CNY · FY for 2025
Figures on this page computed 2026-11-08 07:45 UTC
Last close
n/aCNY
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
14.4xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
54.6%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
8.8%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
20.5%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.25Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
2.3%Dividend yield
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Growth is the furthest below its sector's middle: 0.34 against 0.47 on the market's range.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales1.10x
Its own average over 10 years, 13.77B.
- Profit1.09x
Its own average over 10 years, 1.23B.
- Free cash flow1.57x
Its own average over 10 years, 2.00B.
- Debt1.06x
Its own average over 10 years, 3.63B.
- Pricen/a
Its own average over 0 years. Market data
Free cash flow is furthest from its own average, at 1.57 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-12-31 | 100.0 | 100.0 | 100.0 |
| 2017-12-31 | 110.9 | 472.5 | 90.9 |
| 2018-12-31 | 115.2 | 154.9 | 94.5 |
| 2019-12-31 | 123.2 | 198.1 | 112.5 |
| 2020-12-31 | 139.1 | 248.2 | 113.3 |
| 2021-12-31 | 163.6 | 294.3 | 112.2 |
| 2022-12-31 | 176.3 | 332.9 | 109.9 |
| 2023-12-31 | 171.2 | 319.6 | 110.0 |
| 2024-12-31 | 160.7 | 307.2 | 108.6 |
| 2025-12-31 | 156.5 | 295.9 | 106.0 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Figures behind the shape
Growth
2.4%faster is higher, placed against 4,950 companies as of 2026-11-07
Five-year revenue growth rate2.4%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Five-year EPS growth rate4.7%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
One-year change in net income-3.7%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Returns on capital
54.6%higher is higher, placed against 5,089 companies as of 2026-11-07
Return on invested capital54.6%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity8.8%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets3.8%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
62.4%wider is higher, placed against 3,412 companies as of 2026-11-07
Gross margin62.4%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin22.8%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin8.8%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin20.5%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
14.4xcheaper is higher, placed against 4,362 companies as of 2026-11-07
Price to earnings14.4x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
Price to book1.3x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA2.2x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio1.3x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
0.25safer is higher, placed against 3,227 companies as of 2026-11-07
Debt to equity0.25
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio2.62
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage39.8x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score2.73
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
2.3%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-07
Dividend yield2.3%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Payout ratio33.5%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio7.0x
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.